Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17447494 | 0.89 | CNR1 (0.42) | MEN1KMT2ATDP1CNR1ALDH1A1 | |
| SCHEMBL19176866 | 0.85 | CNR1 (0.32) | CNR1ALDH1A1 | |
| SCHEMBL19137904 | 0.84 | RIPK1 (0.44) | CNR1ALDH1A1DRD2DRD4CCR2 | |
| SCHEMBL17447534 | 0.81 | DRD2 (0.39) | MEN1KMT2ATDP1CNR1ALDH1A1 | |
| SCHEMBL17676858 | 0.80 | MEN1 (0.37) | MEN1KMT2ATDP1CNR1ALDH1A1 | |
| SCHEMBL16943871 | 0.80 | MEN1 (0.37) | MEN1KMT2ATDP1CNR1ALDH1A1 | |
| SCHEMBL13036470 | 0.79 | MEN1 (0.47) | MEN1KMT2ATDP1CNR1ALDH1A1 | |
| SCHEMBL23502424 | 0.78 | MEN1 (0.41) | MEN1KMT2ATDP1CNR1ALDH1A1 | |
| SCHEMBL17447485 | 0.78 | TDP1 (0.41) | MEN1KMT2ATDP1CNR1ALDH1A1 | |
| SCHEMBL23798597 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| WO-2016008582-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | MEN1 4070/4885KMT2A 2875/4885TDP1 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.